Form 4: SELLAS Life Sciences Director Awarded Stock and Options
SEC Form 4 Filing
Katherine Bach Kalin, a director at SELLAS Life Sciences Group, received 12,500 restricted stock units and options to purchase 18,500 shares.
Summary
- Katherine Bach Kalin, a director at SELLAS Life Sciences Group, was granted 12,500 restricted stock units on January 10, 2025.
- These restricted stock units will vest fully on December 1, 2025, contingent on her continued service on the board.
- Ms. Kalin also received options to purchase 18,500 shares of common stock at an exercise price of $0.9525 per share.
- These options will vest on the earlier of January 10, 2026, or the day before the 2026 annual stockholders meeting, also subject to her continued board service.
- The options expire on January 10, 2035.
Sentiment
Score: 7
Explanation: The document reflects standard corporate practice for director compensation, which is generally viewed positively as it aligns interests. There are no negative implications.
Positives
- The grant of stock and options aligns the director's interests with those of the shareholders.
- The vesting conditions encourage continued service on the board.
Industry Context
This type of equity compensation is common for directors of publicly traded companies, aligning their interests with shareholders and incentivizing performance.
Comparison to Industry Standards
- Equity grants to directors are a standard practice in the biotechnology industry, often including a mix of restricted stock units and stock options.
- The vesting schedules are typical, with vesting contingent on continued service to ensure long-term commitment.
- The exercise price of $0.9525 for the options is a common practice, often set at or near the market price at the time of grant.
Stakeholder Impact
- Shareholders may view this as a positive sign of aligning director interests with company performance.
- Employees may see this as a standard practice for director compensation.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of grant for restricted stock units and stock options. |
| 01/14/2025 | Date of the power of attorney execution. |
| 12/01/2025 | Vesting date for the restricted stock units. |
| 01/10/2026 | First possible vesting date for the stock options. |
| 01/10/2035 | Expiration date for the stock options. |
Keywords
stock options, restricted stock units, director compensation, insider trading, SELLAS Life Sciences, equity awards, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.